Cargando…
Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists
Various criteria are necessary to assess the efficacy and safety of biological medications in order to grant companies the right to register these medications with the appropriate bodies that regulate their sale. The imminent expiration of the patents on reference biological products which block the...
Autores principales: | Urbano, Paulo César Martins, Soccol, Vanete Thomaz, Azevedo, Valderilio Feijó |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124053/ https://www.ncbi.nlm.nih.gov/pubmed/25114503 http://dx.doi.org/10.2147/BTT.S57253 |
Ejemplares similares
-
Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014) -
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021) -
The biosimilars journey: current status and ongoing challenges
por: Kos, Igor Age, et al.
Publicado: (2018) -
Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market
por: Scheinberg, Morton Aaron, et al.
Publicado: (2018) -
Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2019)